Aurora Cannabis (ACB, Financial) experienced significant stock movement with a notable 5.12% increase in share price, reaching $3.64 per share. The trading volume was approximately 593,516 shares, with a turnover rate of 1.08% and a price fluctuation of 5.20%.
Recent financial reports show Aurora Cannabis achieved a revenue of $59.47 million, a net profit of $1.91 million, and an earnings per share of -$0.16. The gross profit stood at $586,521.99, while the price-to-earnings ratio was -5.56. Among the six institutions that rated the stock, 33% recommended buying, and 67% suggested holding, with no sell recommendations.
In the broader pharmaceutical industry, where Aurora Cannabis operates, the overall increase was 0.50%. Among related stocks, Quantum Biopharma Ltd., Cumberland Pharmaceuticals, and Medicus Pharma Ltd. showed significant gains. Quantum Biopharma Ltd., Cumberland Pharmaceuticals, and Nature's Sunshine Products were notably active, with turnover rates of 2810.06%, 79.34%, and 17.76%, respectively. Quantum Biopharma Ltd., Scilex Holding Company, and Cumberland Pharmaceuticals exhibited substantial volatility with price fluctuations of 42.75%, 34.95%, and 23.90%, respectively.
Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medical and recreational cannabis through brands such as Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael '71. Although primarily operating in Canada, the company has expanded internationally with medical cannabis export agreements or cultivation facilities in over 20 countries.
